The global economy as we know it is dying. Around the beginning of the 18th century, a “Great Divergence” began between ‘the West and the Rest’ – one that tipped the global socioeconomic scales for ...

By now, ChatGPT, Claude, and other large language models have accumulated so much human knowledge that they're far from simple answer-generators; they can also express abstract concepts, such as ...

It’s more than just code. Scientists have found a way to "dial" the hidden personalities of AI, from conspiracy theorists to social influencers.

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Abstract: Walsh-Hadamard transform (WHT) has many applications in digital signal processing including bioinformatics. While there are efficient algorithms for implementing this transform such as fast ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Cryptography secures communication in banking, messaging, and blockchain. Good algorithms (AES, RSA, ECC, SHA-2/3, ChaCha20) are secure, efficient, and widely trusted. Bad algorithms (DES, MD5, SHA-1, ...

MicroAlgo Inc. announced its research on the Quantum Information Recursive Optimization (QIRO) algorithm, which aims to address complex combinatorial optimization problems using quantum computing.

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...